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Effects, equity, and cost of school-based and 
community-wide treatment strategies for soil-transmitted 
helminths in Kenya: a cluster-randomised controlled trial
Rachel L Pullan, Katherine E Halliday, William E Oswald, Carlos Mcharo, Emma Beaumont, Stella Kepha, Stefan Witek-McManus, Paul M Gichuki, 
Elizabeth Allen, Tom Drake, Catherine Pitt, Sultani H Matendechero, Marie-Claire Gwayi-Chore, Roy M Anderson, Sammy M Njenga, 
Simon J Brooker*, Charles S Mwandawiro*
Summary
Background School-based deworming programmes can reduce morbidity attributable to soil-transmitted helminths 
in children but do not interrupt transmission in the wider community. We assessed the effects of alternative mass 
treatment strategies on community soil-transmitted helminth infection.
Methods In this cluster-randomised controlled trial, 120 community units (clusters) serving 150 000 households in 
Kenya were randomly assigned (1:1:1) to receive albendazole through annual school-based treatment targeting 
2–14 year olds or annual or biannual community-wide treatment targeting all ages. The primary outcome was 
community hookworm prevalence, assessed at 12 and 24 months through repeat cross-sectional surveys. Secondary 
outcomes were Ascaris lumbricoides and Trichuris trichiura prevalence, infection intensity of each soil-transmitted 
helminth species, and treatment coverage and costs. Analysis was by intention to treat. This trial is registered with 
ClinicalTrials.gov, number NCT02397772.
Findings After 24 months, prevalence of hookworm changed from 18·6% (95% CI 13·9–23·2) to 13·8% (10·5–17·0) 
in the annual school-based treatment group, 17·9% (13·7–22·1) to 8·0% (6·0–10·1) in the annual community-wide 
treatment group, and 20·6% (15·8–25·5) to 6·2% (4·9–7·5) in the biannual community-wide treatment group. 
Relative to annual school-based treatment, the risk ratio for annual community-wide treatment was 0·59 (95% CI 
0·42–0·83; p<0·001) and for biannual community-wide treatment was 0·46 (0·33–0·63; p<0·001). More modest 
reductions in risk were observed after 12 months. Risk ratios were similar across demographic and socioeconomic 
subgroups after 24 months. No adverse events related to albendazole were reported.
Interpretation Community-wide treatment was more effective in reducing hookworm prevalence and intensity than 
school-based treatment, with little additional benefit of treating every 6 months, and was shown to be remarkably 
equitable in coverage and effects.
Funding Bill & Melinda Gates Foundation, the Joint Global Health Trials Scheme of the Medical Research Council, 
the UK Department for International Development, the Wellcome Trust, and the Children’s Investment Fund 
Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under CC-BY 4.0 license.
Introduction
In 2012, the London Declaration on neglected tropical 
diseases announced a cross-sectoral commitment to 
control or eliminate ten neglected tropical diseases 
by 2020, on the basis of WHO roadmap targets.1 For 
soil-transmitted helminths (which include Ascaris 
lumbricoides, Trichuris trichiura, and the hookworms 
Ancylostoma duodenale and Necator americanus), the target 
is to provide regular anthelmintic treatment to at least 
75% of children aged 1–14 years in districts where 
prevalence of any soil-transmitted helminth infection 
exceeds 20% in schoolchildren, with a view to controlling 
the morbidity associated with infection.2 By 2016, school-
based deworming programmes had reached 69·5% of 
these children, with 33 of the 102 countries requiring 
preventive chemotherapy exceeding the 75% coverage 
target.3 Building upon this progress, national programmes 
and policy makers are now looking beyond 2020 and 
towards goals focused on reducing transmission. Mathe-
matical models suggest that community-wide treatment 
can interrupt soil-transmitted helminth transmission4,5 
and a meta-analysis suggests it would be more effective 
than school-based treatment in reducing infection among 
school-age children.6
Other neglected tropical disease programmes, including 
those against onchocerciasis, trachoma, and lymphatic 
filariasis, have achieved treatment of entire com munities 
with community health workers or volunteers, using 
central point or house-to-house delivery models. In 
addition to providing a platform for reducing community 
infection levels, these programmes might provide an 
important gateway to universal health coverage, through 
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ensuring broad, equitable access to basic health services, 
particularly among the most marginalised populations.7,8 
For this reason, neglected tropical disease treatment 
coverage has been included as an equity tracer for 
the Sustainable Development Goal target 3.8 (achieving 
universal health coverage).9 However, evidence of the 
equity of mass drug administration programmes within 
targeted communities is insufficient, both in terms of 
coverage and effects on infection outcomes.
We did a cluster-randomised trial on the Kenyan coast 
to evaluate and compare the effects, equity, and cost of 
annual school-based treatment, annual community-wide 
treatment, and biannual community-wide treatment in 
reducing the prevalence and intensity of soil-transmitted 
helminth infection.
Methods
Study design
TUMIKIA (Tuangamize Minyoo Kenya Imarisha Afya; 
Swahili for Eradicate Worms in Kenya for Better Health) 
was a cluster-randomised controlled trial done in Kwale 
County from March 18, 2015, to May 17, 2017. We 
originally planned to do the trial in two contrasting 
settings, but financial and practical considerations meant 
we prioritised work in Kwale, which had benefited 
from previous mass drug administration for lymphatic 
filariasis. The county is mostly rural and environmentally 
and socioeconomically diverse. Hookworm is the pre-
dominant soil-transmitted helminth species. Annual 
school-based deworming with albendazole has been 
implemented since 2012,10 and community-based 
treatment for lymphatic filariasis using albendazole 
and diethylcarbamazine citrate since 2002, albeit 
intermittently and with low coverage.11 Mass treatment 
is a community-level intervention so we did a cluster-
randomised trial; the study objectives pertain to the 
individual participant level. The unit of randomisation 
was a community unit, a government health-service 
delivery structure serving approximately 1000 households. 
All community units in Kwale county were eligible for 
enrolment. The rationale and study design have been 
published previously.12
The protocol was approved by the Kenya Medical 
Research Institute and National Ethics Review Com-
mittee (SSC Number 2826) and the London School of 
Hygiene & Tropical Medicine Ethics Committee (7177). An 
independent data safety monitoring board monitored the 
trial and approved the statistical analysis plan. Community 
meetings were held to explain the nature and purpose of 
the trial to community members and parents or legal 
guardians, and written informed consent was obtained for 
participation in assessment surveys and verbal consent for 
treatment. No incentives were offered for participation.
Randomisation and masking
Households were enumerated in consultation with both 
community health services-led and village-led adminis-
tration, to provide a baseline sampling frame. This 
Research in context
Evidence before this study
The focus of control efforts for soil-transmitted helminths is 
annual school-based deworming, but mathematical modelling 
suggests that this strategy is unlikely to interrupt transmission, 
necessitating ongoing investment in control. The models 
suggest that interruption of soil-transmitted helminth 
transmission might be feasible if treatment is expanded to adults 
and provided more frequently, but empirical support of this 
hypothesis is scarce. A systematic review and meta-analysis 
suggested that community-wide treatment is more effective 
than school-based treatment in reducing infection among 
school-age children, and a non-randomised community trial of 
biannual mass treatment of all ages showed notable reductions 
in the prevalence of soil-transmitted helminth infection. 
However, available studies do not have adequate control groups 
and randomisation, have not been implemented at scale or in 
programmatic settings, and are under-powered.
Added value of this study
Our trial used a cluster-randomised design and included 
120 randomly assigned community units, all of which were 
included in the analysis. We found that community-wide 
treatment with albendazole was more effective in reducing the 
prevalence and intensity of hookworm among all ages than 
school-based treatment, although biannual treatment had little 
additional benefit. Additionally, we investigated the 
socioeconomic and demographic equity of the intervention and 
found comparable coverage and effects of the interventions 
across important demographic and socioeconomic subgroups. 
Community-based mass drug administration is also used in 
other neglected tropical diseases, including lymphatic filariasis, 
onchocerciasis, and trachoma, which collectively reach more 
than 1 billion people annually. Our results are some of the first 
data highlighting the remarkable equity of the neglected tropical 
disease delivery platform within targeted communities.
Implications of all the available evidence
Our results are consistent with those from previous research on 
mathematical models of soil-transmitted helminth transmission 
and treatment and highlight a role for community-wide 
treatment in reducing prevalence and intensity of hookworm 
infection. These findings are highly relevant to ongoing discourse 
concerning post 2020 WHO goals for soil-transmitted helminths, 
as they highlight the potential of including a transmission goal in 
some settings. Our finding of the equity of the intervention 
illustrates the reach and equity of the neglected tropical disease 
delivery platform and the potential to leverage this platform to 
deliver other health interventions among the poorest, most 
marginalised communities, and thus contribute towards 
universal health-care coverage.
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baseline sampling frame was updated after each round of 
community-wide treatment using household treatment 
registers. Random assignment of study clusters (1:1:1) to 
routine school-based treatment, annual community-wide 
treatment, or biannual community-wide treatment took 
place after the baseline survey and was stratified by 
combining subcounty (n=4), hookworm prevalence (below 
and above 20%, determined in the baseline survey, n=2), 
and community unit size (below and above a median of 
840 households, n=2), leading to 16 strata. Randomisation 
took place within strata and was done by an indepen-
dent statistician using computerised random number 
generation. Owing to the nature of the trial, participants 
and trial personnel were not masked to allocation, 
although the identity of the study groups was hidden 
until the completion of stakeholder engagement and 
the baseline survey to eliminate participation bias. 
Community health volunteers and teachers who delivered 
the treatments were not involved in data collection and 
laboratory technicians and statisticians were blinded to 
treatment group.
Procedures
In total, there were four rounds of treatment in the 
2 years. All trial groups received directly observed 
treatment with albendazole (400 mg) provided from 
the WHO donation programme to the Government of 
Kenya through GlaxoSmithKline (London, UK). Trial 
groups differed by the age range of the target population 
and the number of treatment rounds in which they were 
included.
In rounds one (June 4, 2015) and three (May 26, 2016), 
school-based de worming targeting children aged 
2–14 years was provided to all groups as part of the 
ongoing National School-Based Deworming Programme 
(NSBDP). On designated deworming days, treatment 
was offered by trained teachers in primary schools to 
enrolled and non-enrolled children and younger children 
in nearby Early Childhood Development Centres. After 
school-based deworming, the annual community-wide 
treatment and biannual community-wide treatment 
groups received community-based (house-to-house) 
treatment delivered to all individuals aged 2 years and 
above not treated by the NSBDP. The Kwale County 
Government coordinated these activities. Treatment was 
delivered by trained community health volunteers, a 
cadre of lay health workers selected by their communities 
to provide basic health services. Each community health 
volunteer received one day of training on the delivery of 
community-based treatment and was then responsible 
for treating approximately 100 households over an 8-day 
period.
In round two (Nov 23–30, 2015), the national lymphatic 
filariasis elimination programme used the afore-
mentioned community-based delivery model to target 
individuals aged 2 years and older with diethylcarbamazine 
citrate (6 mg/kg) and albendazole in the biannual 
community-wide treatment group. To preserve the trial 
design, albendazole was withheld from the school-based 
deworming and annual community-wide treatment 
groups, and diethylcarbamazine citrate monotherapy 
offered. In round four (Oct 28–Nov 4, 2016), only the 
biannual community-wide treatment group was targeted 
with diethylcarbamazine citrate and albendazole; no 
community-based treatment was done in the other 
two groups because it was delayed until after the final 
assessment survey. Further details on intervention 
delivery are provided in the appendix.
Pregnant women and women who had given birth 
within the past 2 weeks, and those individuals who were 
seriously ill were ineligible for treatment, due to concerns 
around the perceived risks of treatment in the study 
community and absence of clear operation guid ance on 
how to safely reach pregnant women. Passive monitoring 
of adverse events and severe adverse events was carried 
out during treatment activities. Before each treatment 
round, teachers and community health volunteers were 
trained to recognise and report adverse events and severe 
adverse events during treatment and follow-up visits, 
with any severe adverse events arising collated by trial 
staff, who in turn reported to the data safety monitoring 
board and Kenya Ministry of Health.
In a change from the published protocol,12 cross-
sectional community assessment surveys were done after 
12 and 24 months; a third assessment survey after 
30 months was not possible due to implementation 
schedules for the national soil-transmitted helminth 
and lymphatic filariasis control and elimination pro-
grammes. The baseline, 12-month and 24-month asses-
sment surveys were done during the 2 months before the 
NSBDP deworming days (March 18–June 2, 2015, 
March 20–May 12, 2016, and March 14–May 17, 2017). In 
each community unit, 225 households were randomly 
selected from the enumeration listing. Households were 
excluded if the dwelling could not be found, was vacant, 
or if no adult resident was home on more than three 
visits. Household locations were mapped using global 
positional system coordinates. Household members were 
enumerated, and a household survey was used to collect 
data on water and sanitation facilities and proxy indicators 
of wealth. One household member was randomly selected 
and asked to provide a stool sample, collected in a plastic 
pot labelled with a unique identi fication matrix barcode. 
Call-backs were arranged either later in the day or early 
the next day for individuals that could not provide a 
sample immediately. If the selected individual was 
unwilling or unable to participate, another household 
member was randomly selected. Stool samples were 
transported on the day of collection to a local laboratory, 
where they were immediately examined microscopically 
in duplicate using Kato-Katz method, in which slides 
were examined for hookworm within 1 h of preparation. 
A senior technician re-examined 10% of slides for 
quality control.
See Online for appendix
Articles
4 www.thelancet.com   Published online April 18, 2019   http://dx.doi.org/10.1016/S0140-6736(18)32591-1
Treatment coverage was assessed through school and 
household coverage surveys, done in all schools in the 
county and all community units in both community-
wide treatment groups following rounds 1 and 3, and in 
all community units in the biannual community-wide 
treatment group following rounds 2 and 4. All coverage 
surveys were completed 4–8 weeks after the treatment 
activities. In schools, class registers were used to 
randomly select 12 children from each of grades 2, 4, 6, 
and 8, who were asked their village of residence, if they 
were present on the deworming day and if they took the 
tablet. In each community unit, 60 households were 
randomly selected, and all household members present 
were asked whether they had been offered deworming 
treatment by a community health volunteer at home 
(or by a teacher at school) and whether they had taken the 
treatment. In both coverage surveys, proxy respondents 
(other household member, peer or teacher) were accepted 
when household members or pupils were unable to 
answer or not present.
All survey and laboratory data generated by study 
personnel were collected on smartphones and uploaded 
to a dedicated database maintained on a central server 
(SurveyCTO, Dobility, Inc, Cambridge, MA); field and 
laboratory results were linked using the unique 
identification number barcodes provided on the sample 
pots.
Outcomes
The primary outcome was prevalence of hookworm 
infection among all sampled individuals after 12 and 
24 months of intervention. Secondary outcomes were 
prevalence of Ascaris lumbricoides and Trichuris trichiura, 
and intensity of infection for each soil-transmitted 
helminth species, based on quantitative egg counts, 
and treatment coverage and costs. An individual was 
deemed egg positive if one or more eggs were found in 
any of the slides examined. The intensity of infection 
was expressed as the number of eggs per gram of stool 
for each helminth species.
Treatment coverage in household and school coverage 
surveys was calculated as the proportion of consenting 
individuals aged 2 years or older (or assenting school-
going children) who usually lived in surveyed households 
(or attended surveyed schools) and who reported being 
offered treatment that they accepted to swallow, by a 
community health volunteer at home or by a teacher at 
school. Coverage was calculated overall by group and by 
round, and within age strata—2–4 years, 5–14 years, and 
≥15 years, adolescent girls (10–19 years), and women of 
child bearing age (15–49 years). We also calculated total 
and average cost per person treated per round by 
community-based (house-to-house) treatment.
Statistical analysis
Based on a prevalence of 15% at baseline, an intra-cluster 
correlation coefficient (ICC) of 0·125 and 5% loss to 
follow-up of community units, a sample size of 40 clusters 
per group provides 80% power to detect differences 
between groups of 8% with a significance level of 0·025 to 
allow for multiple com parisons. The assumed differences 
between groups lie well within the range predicted by 
stochastic models of parasite transmission and treatment 
by alternative strategies.12 Prevalence of infection was 
Figure 1: Study profile
120 community units were randomly assigned to either routine school-based deworming or community-wide 
treatment delivered once or twice a year. No community units were lost to follow up, and none discontinued the 
intervention. All communities were included in the analysis at 12 and 24 months. Reported cluster sizes are based 
on the updated sampling frame used for the 24-month evaluation survey. Additional information regarding 
households and individuals not reached are provided in appendix.
Biannual community-wide 
treatment
40 community units;
50 063 households (median by
CU 1157; range 360–3391)
Discontinued intervention
0 community units 
Soil-transmitted helminth 
assessments 
40 community units analysed
Individuals analysed
Baseline (March 18–June 2, 2015)
6765 analysed
432 households not 
reached
710 responsible adults 
unavailable or refused
213 sampled individuals 
unavailable or refused
1007 no parasitology data
Year 1 (March 20–May 12, 2016)
8289 analysed
485 households not 
reached
756 responsible adults 
unavailable or refused
261 sampled individuals 
unavailable or refused
324 no parasitology data
Year 2 (March 14–May 17, 2017)
7408 analysed
2788 households not 
reached
892 responsible adults 
unavailable or refused
424 sampled individuals 
unavailable or refused
662 no parasitology data 
Annual community-wide 
treatment
40 community units;
49 726 households (median by
CU 1241; range 363–3082)
Discontinued intervention
0 community units 
 
120 community units ramdomly 
assigned (1:1:1) 
10 community units excluded
3 extreme rural
4 urban centres
3 randomly deselected 
Soil-transmitted helminth 
assessments 
40 community units analysed
Individuals analysed
Baseline (March 18–June 2, 2015)
6523 analysed
488 households not 
reached
674 responsible adults 
unavailable or refused
236 sampled individuals 
unavailable or refused
1060 no parasitology data
Year 1 (March 20–May 12, 2016)
8449 analysed
342 households not 
reached
737 responsible adults 
unavailable or refused
246 sampled individuals 
unavailable or refused
317 no parasitology data
Year 2 (March 14–May 17, 2017)
7593 analysed
2326 households not 
reached
891 responsible adults 
unavailable or refused
292 sampled individuals 
unavailable or refused
540 no parasitology data
130 community units defined 
and assessed for eligibility
84 functional
12 non-functional
34 newly formed 
Routine school-based 
deworming
40 community units; 
47 674 households (median by
CU 1037; range 276–2940)
Discontinued intervention
0 community units 
Soil-transmitted helminth 
assessments 
40 community units analysed
Individuals analysed
Baseline (March 18–June 2, 2015)
6396 analysed
531 households not 
reached
650 responsible adults 
unavailable or refused
177 sampled individuals 
unavailable or refused
1037 no parasitology data
Year 1 (March 20–May 12, 2016)
8105 analysed
382 households not 
reached
888 responsible adults 
unavailable or refused
279 sampled individuals 
unavailable or refused
328 no parasitology data
Year 2 (March 14–May 17, 2017)
7187 analysed
2763 households not 
reached
953 responsible adults 
unavailable or refused
367 sampled individuals 
unavailable or refused
547 no parasitology data
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School-based deworming Annual community-wide 
treatment
Biannual community-wide 
treatment
Cluster characteristics (n=120)
Total included 40 40 40
Sanitation coverage* 53·5% (2·1%–98·3%) 53·0% (5·3%–92·8%) 49·7% (1·4%–96·2%)
Urban† 4 (10·0%) 2 (5·0%) 3 (7·5%)
Hard to reach‡ 3 (7·5%) 4 (10·0%) 4 (10·0%)
Arid§ 7 (17·5%) 3 (7·5%) 5 (12·5%)
Households surveyed (n=23 414)
Total included 7610 7819 7985
Number of household members 5 (1–22) 5 (1–23) 5 (1–21)
Asset index score¶ 0·47 (–0·01 to 2·21) 0·47 (–0·01 to 2·21) 0·47 (–0·01 to 2·21)
Living in poorest quintile|| 2339 (30·7%) 2407 (30·8%) 2394 (30·0%)
Electricity to household 742 (9·8%) 690 (8·8%) 706 (8·8%)
Owns a bicycle 2315 (30·4%) 2445 (31·3%) 2455 (30·8%)
Earth floor 5797 (76·2%) 6270 (80·2%) 6234 (78·1%)
Household toilet facility access
None 3463 (45·5%) of 7605 3546 (45·4%) of 7816 4035 (50·6%) of 7977
Shared access 1801 (23·7%) of 7605 1907 (24·4%) of 7816 1855 (23·3%) of 7977
Private access 2341 (30·8%) of 7605 2363 (30·2%) of 7816 2087 (26·2%) of 7977
Soap and water observed at toilet** 255 (8·2%) of 3095 227 (7·2%) of 3175 207 (6·9%) of 2998
Toilet facility has washable slab†† 1768 (56·1%) of 3150 1534 (47·5%) of 3230 1662 (54·7%) of 3039
Improved water source 3977 (52·6%) of 7556 4589 (58·8%) of 7800 4022 (50·4%) of 7978
Water source <30 min 6138 (81·2%) of 7561 6322 (81·2%) of 7789 6383 (80·4%) of 7940
Survey participants (n=22 788)
Total included 7433 7583 7772
Male/female participants 3017 (40·6%)/4416 (59·4%) 3069 (40·5%)/4514 (59·5%) 3102 (39·9%)/4670 (60·1%)
<5 years 630 (8·5%) 599 (8·0%) 622 (8·0%)
5–14 years 2197 (29·6%) 2321 (30·6%) 2378 (30·6%)
≥15 years 4606 (62·0%) 4663 (61·5%) 4772 (61·4%)
Attending primary school (ages 5–14 yrs) 1980 (90·1%) of 2197 2098 (90·4%) of 2321 2126 (89·4%) of 2378
Observed wearing shoes 3500 (47·2%) 3416 (45·1%) 3406 (43·9%)
Dewormed in past year: 1814 (24·6%) 1905 (25·4%) 1966 (25·6%)
At school 1204 (66·4%) of 1814 1352 (71·1%) of 1905 1337 (68·0%) of 1966
At health centre 359 (19·8%) of 1814 358 (19·0%) of 1905 380 (19·3%) of 1966
Other location or source 251 (13·8%) of 1814 193 (10·1%) of 1905 249 (12·7%) of 1966
Participants with soil-transmitted helminth data (n=19 684)
Total included 6396 6523 6765
Prevalence of soil-transmitted helminth infection
Hookworm 1187 (18·6%) 1168 (17·9%) 1396 (20·6%)
Ascaris lumbricoides 30 (0·5%) 18 (0·3%) 30 (0·4%)
Trichuris trichiura 272 (4·3%) 189 (2·9%) 250 (3·7%)
Mean intensity of soil-transmitted helminth infection (eggs per gram)
Hookworm 169·7 (1248·2) 175·1 (1965·2) 158·2 (1002·3)
Ascaris lumbricoides 62·6 (2023·3) 18·9 (648·2) 31·0 (808·7)
Trichuris trichiura 12·7 (205·0) 8·3 (145·0) 29·3 (1245·8)
Data are n (%), median (range), or mean (SD). Data were collected during a household-based cross-sectional survey done from March, 2015, to May, 2015. *Defined as the 
proportion of households who report having access to a toilet facility. †Defined as >75% households in areas with population density >1000 persons per km². ‡Defined as 
>75% of households <4 km from major road. §Defined as >75% households in arid or semi-arid areas. ¶Based on factor analysis of owned assets and household structure. 
||From asset index score. **Data available for 9268 households with toilet and handwashing facilities on premises that agreed to direct observation. ††Data available for 
9419 households with toilet facilities on premises that agreed to direct observation.
Table 1: Baseline characteristics of the study population
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higher than expected at baseline, the ICC was higher than 
expected (at 0·238), and variation in cluster size greater 
than expected, although this did not unduly affect sample 
size calculations. Treatment coverage surveys were 
powered at 80% to provide estimates with ±2% precision, 
assuming a mean coverage of 70% and an ICC of 0·04 in 
school surveys, and a mean coverage of 50% and an ICC 
of 0·01 in household surveys. ICC values used in sample 
size calculations were based on unpublished school and 
community survey data provided by the NSBDP. Analyses 
were done on an intention-to-treat basis, excluding 
individuals without egg count data from at least one slide.
For prevalence of infection, generalised estimating 
equations were used to estimate the difference between 
treatment groups after 1 and 2 years of intervention. For 
infection intensity, zero-inflated negative binomial models 
were used modelling total numbers of eggs observed, 
adjusting for inflation using age, sex, and cluster-level 
prevalence at baseline, and including number of grams of 
stool examined as an offset (to account for cases in which 
only one slide was read). For both models, we estimated 
standard errors and confidence intervals using robust 
standard errors (the Huber-White Sandwich estimator) 
to account for correlated outcomes at the level of the 
community unit. Unadjusted results used only study 
group as covariates, and adjusted estimates included 
stratification factors (subcounty, cluster-level prevalence 
at baseline, and cluster size), rural or urban status, 
mean cluster-level socioeconomic status, and access to 
any sanitation and improved water-source at baseline 
(specified a priori).
Prespecified subgroup analyses were done using 
formal statistical tests of interaction to compare the 
consistency (equity) of intervention effects between 
male and female individuals, socioeconomic strata 
(defined using a factor analysis of owned assets and 
household structure performed separately for rural and 
urban clusters), households with and without re ported 
sanitation access, school-enrolled and non-enrolled 
children (ages 2–14 years) and adults (aged ≥15 years), 
and remote (>4 km from a major road) and accessible 
(≤4 km from a major road) households. Data man-
agement and statistical analyses were done using 
Stata 15.
Economic analysis
Economic analysis was restricted to community-based 
treatment approaches, because school-based deworming 
was not managed by the research team so cost data were 
not readily available. An ingredients-based approach was 
used to estimate the cost to the provider of treatment 
delivered by community health volunteers in rounds 3 
and 4 in 2016. Details are provided in the appendix. In 
brief, both financial costs, which reflect actual monies 
paid, and economic costs, which reflect the full value of 
all resources used, were estimated. Costs relating only to 
research activities were excluded. Data were collected 
through routine trial reporting and evaluation systems, 
reviewing financial reports, and key informant interviews. 
Community health volunteers’ time was valued using an 
opportunity cost approach. All activities were considered 
recurrent. The value of capital goods was annualised over 
their useful lifespan using a discount of 3%.13 Costs 
were categorised both by activity and by resource type 
and estimated for each treatment cluster and group. 
To compare the costs of community-based delivery 
alongside or instead of school-based delivery, the within-
cluster differences in average costs per person treated 
were compared between delivery rounds for the biannual 
group, using a paired t test to construct a confidence 
interval for the cost difference at the 5% level. Univariate 
sensitivity analysis was done on selected key parame-
ters, including the shadow price of albendazole, daily 
allowances given to community health volunteers, and 
discount and exchange rates. Costs are presented in 
constant 2016 US$ ($1=101·50 Kenyan shillings14).
In addition to treatment costs in the trial, we estimated 
costs for routine programmatic delivery. These were 
estimated firstly by removing or modifying costs that 
would not be incurred outside the trial, and secondly, by 
accounting for economies of scale that would be achieved 
if the same intervention strategy were extended to all 
clusters within Kwale County. Specifically, we assumed 
that the county-level costs, primarily for meetings, would 
remain fixed, and multiplied the average cost per 
Figure 2: Map of the study area
Kwale County consists of four subcounties, all of which were included in the trial. The inset shows the location of 
Kwale County in Kenya.
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subcounty and per community unit by the numbers of 
subcounties and community units in the entire county. 
Econcomic analyses were done using Microsoft Excel 
Professional Plus 2016 and RStudio (Version 1.1.453).
This trial is registered with ClinicalTrials.gov, number 
NCT02397772
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Of the 130 eligible community units, 120 were included in 
the study and randomly assigned (figure 1), with seven geo-
graphically sparse or urban community units excluded and 
three community units removed through random dese-
lection. No community units were lost to follow-up during 
the trial. At the final community survey, 147 463 house-
holds were listed in the study area (appendix).
The baseline survey included 19 684 individuals with 
soil-transmitted helminth data (table 1; appendix). 
Baseline and demographic characteristics were similar 
across all three groups. Overall prevalence of hookworm 
was 19·1% (95% CI 16·4–21·7) and prevalence of 
T trichiura was 3·6% (2·6–4·6). A lumbricoides was very 
rare (prevalence <0·5%) and was not analysed further.
All 120 community units received the interventions to 
which they were randomly assigned (figure 2). Treatment 
coverage remained relatively consistent across rounds 
(table 2). Coverage of school-enrolled children aged 
5–14 years through school-based deworming was 88·2% 
(95% CI 87·6–88·7) in May, 2016, and 88·0% (87·5–88·5%) 
in May, 2017, as reported during school surveys, and did 
not differ by trial group. Estimates from school surveys 
were similar to those from household surveys after 
accounting for school enrolment rates (appendix).
Coverage of the eligible population in the annual 
community-wide treatment group was 80·7% (95% CI 
79·1–82·2) in 2015 and 82·9% (81·5–84·3) in 2016, and 
ranged from 74·0% (71·5–76·5) to 83·0% (81·7–84·3%) 
across the four rounds in the biannual community-wide 
treatment group (table 2). Community health volunteers 
reached more than 88% of households in each treatment 
round, and coverage did not fall below 70% in any of the 
demographic groups considered.
Annual community-wide treatment arm Biannual community-wide treatment arm
Round 1 Round 3 Round 1 Round 2 Round 3 Round 4
Households reporting community 
health volunteer visit
2074 (90·8%) 2375 (95·2%) 2074 (91·4%) 2174 (88·3%) 2330 (95·3%) 2112 (92·6%)
Eligible individuals interviewed 12 102 12 227 11 453 11 276 11 908 11 122
Eligible population treatment 
coverage
9765 (80·7%) 10 140 (82·9%) 9220 (80·5%) 8701 (77·2%) 9882 (83·0%) 8231 (74·0%)
Treatment coverage by age group
Pre-school-aged children (2–4 years)
Treated (total) 83·1% (80·2–86·0) 77·8 (74·3–81·2) 84·0% (81·3–86·6) 77·3% (72·7–81·8) 79·2% (76·4–82·1) 73·8% (69·5–78·0)
In school 15·1% (12·9–17·3) 14·5% (12·0–16·9) 15·6% (12·9–18·2) ·· 14·5% (12·1–17·0) ··
At home 68·0% (64·9–72·8) 62·7% (58·8–66·6) 68·4% (65·4–73·5) ·· 64·6% (61·6–67·6) ··
School-aged children (5–14 years)
Treated (total) 91·0% (88·9–93·1) 89·5% (87·1–91·8) 90·5% (88·5–92·4) 81·8% (78·5–85·0) 89·6% (87·2–91·9) 79·9% (76·8–83·0)
In school 68·8% (65·8–71·8) 66·5% (63·3–69·7) 65·8% (62·4–69·2) ·· 64·8% (60·2–69·4) ··
At home 25·1% (22·2–28·1) 21·4% (18·6–84·2) 24·7% (23·8–31·0) ·· 23·8% (20·3–27·3) ··
Adults (≥15 years)
Treated (total) 73·7% (72·0–75·4) 79·7% (78·4–81·1) 74·2% (72·3–76·0) 74·5% (71·6–77·3) 79·6% (78·1–81·2) 70·4% (67·7–73·0)
In school 10·8% (9·8–11·8) 7·7% (6·9–8·6) 9·3% (8·4–10·2) ·· 7·7% (6·8–8·5) ··
At home 63·0% (61·3–65·5) 71·7% (70·0–73·4) 64·9% (63·2–67·3) ·· 71·5% (70·0–73·1) ··
Adolescent girls (10–19 years)
Treated (total) 81·1% (78·5–83·7) 84·4% (82·0–86·7) 81·7% (79·2–84·3) 79·0% (75·9–82·0) 85·1% (82·7–87·4) 78·0% (74·6–81·4)
In school 59·6% (56·0–63·1) 55·2% (52·0–58·4) 57·0% (53·5–60·5) ·· 55·8% (51·3–60·4) ··
At home 21·51% (20·7–26·5) 27·9% (24·8–31·1) 27·1% (24·0–30·2) ·· 28·5% (25·4–31·7) ··
Women of reproductive age (15–49 years)
Treated (total) 73·7% (71·7–75·7) 81·6% (80·0–83·2) 74·1% (71·8–76·4) 75·1% (72·3–77·9) 80·4% (78·6–82·2) 73·1% (70·1–76·1)
In school 11·3% (9·8–12·9) 8·0% (7·0–9·0) 9·7% (8·5–10·9) ·· 8·0% (6·8–9·1) ··
At home 62·4% (60·3–65·2) 73·2% (71·2–75·2) 64·4% (62·8–67·0) ·· 72·1% (70·4–73·7) ··
Coverage data are stratified by trial target populations (pre-school-aged children, school-aged children, and adults) and additional WHO-defined target groups (adolescent girls and women of reproductive age).
Table 2: Reported treatment coverage
Articles
8 www.thelancet.com   Published online April 18, 2019   http://dx.doi.org/10.1016/S0140-6736(18)32591-1
The 12-month assessment survey included 24 843 indi-
viduals, and the 24-month assessment surveys included 
22 188 (figure 1; appendix). Characteristics of consenting 
households and individuals, and for participants with 
soil-transmitted helminth data who constitute the final 
analysis datasets, are provided in the appendix. Refusal 
rates and household and demographic characteristics 
were similar across all three groups, with adult males 
under-represented. After 2 years of intervention, the 
community prevalence of hookworm was 13·8% (95% CI 
10·5–17·1) in the school-based deworming group, 8·0% 
(6·0–10·1) in the annual community-wide treatment 
group, and 6·2% (4·9–7·5) in the biannual community-
wide treatment group (table 3). Compared with school-
based deworming, risk of hook worm infection was 
reduced in the annual (risk ratio 0·59, 95% CI 0·42–0·83) 
and biannual (0·46, 0·33–0·63) community-wide 
treatment groups (table 3). Intensity of hookworm 
infection among all community members was also 
reduced in the annual community-wide treatment group 
(intensity rate ratio 0·39, 95% CI 0·27–0·55) 
and biannual community-wide treatment groups (0·30, 
0·19–0·48) relative to those community units receiving 
school-based deworming, with the greatest reductions 
observed after 12 months (appendix). Adjusted risk ratio 
and intensity rate ratio were similar in magnitude 
and precision to unadjusted estimates. The prevalence or 
intensity of T trichiura did not differ by treatment group 
(table 3; appendix).
None of the demographic or socioeconomic charac-
teristics we explored were found to influence the reduction 
in hookworm infection risk observed in those receiving 
annual or biannual community-wide treatment relative 
to school-based treatment. Specifically, we found no 
evidence of effect differences between male and female 
individuals, children (both attending and not attending 
school) and adults, those living in the poorest and least 
poor households, those with and without access to private 
sanitation and those living in remote or accessible 
households (appendix). This finding was consistent for 
hookworm infection intensity.
In 2016 (treatment rounds three and four of the trial), 
the economic cost of house-to-house treatment by com-
munity health volunteers in the biannual community-
wide treatment group ($214 589) was 112% greater than 
in the annual community-wide treatment group 
($101 413). The economic cost of house-to-house delivery 
was $0·84 per person treated in the annual community-
Number positive of 
total respondents
Community prevalence 
(95% CI)
Absolute percentage 
change from baseline 
(95% CI)
Unadjusted risk ratio 
(95% CI)
p value Adjusted risk ratio* 
(95% CI)
p value
Hookworm
12-month assessment
School-based deworming 1284 of 7957 16·1% (12·1 to 20·1) –2·4% (–10·9 to 6·1) 1 (ref) ·· 1 (ref) ··
Annual community-wide 
treatment
984 of 8355 11·8% (9·0 to 14·6) –6·1% (–13·6 to –1·3) 0·73 (0·52 to 1·03) ·· 0·77 (0·65 to 0·91) ··
Biannual community-wide 
treatment
836 of 8177 10·2% (7·6 to 12·9) –10·4% (–15·5 to –6·0) 0·64 (0·45 to 0·92) 0·04 0·65 (0·53 to 0·78) <0·001
24-month assessment
School-based deworming 972 of 7058 13·8% (10·5 to 17·0) –4·8% (–13·0 to 3·5) 1 (ref) ·· 1 (ref) ··
Annual community-wide 
treatment
597 of 7446 8·0% (6·0 to 10·1) –9·9% (–16·8 to –3·0) 0·59 (0·42 to 0·83) ·· 0·64 (0·52 to 0·78) ··
Biannual community-wide 
treatment
453 of 7281 6·2% (4·9 to 7·5) –14·4% (–21·4 to –7·4) 0·46 (0·33 to 0·63) <0·001 0·48 (0·41 to 0·57) <0·001
Trichuris trichiura
12-month assessment
School-based deworming 296 of 7957 3·7% (1·8 to 5·7) –0·5% (–6·2 to 5·2) 1 (ref) ·· 1 (ref) ··
Annual community-wide 
treatment
223 of 8355 2·7% (1·7 to 3·6) –0·2% (–4·5 to 4·1) 0·70 (0·37 to 1·32) ·· 1·18 (0·80 to 1·74) ··
Biannual community-wide 
treatment
287 of 8177 3·5% (1·9 to 5·2) –0·2% (–5·6 to 5·2) 0·90 (0·45 to 1·81) 0·47 1·16 (0·82 to 1·65) 0·63
24-month assessment
School-based deworming 292 of 7058 4·1% (1·9 to 6·4) –0·1% (–5·9 to 5·7) 1 (ref) ·· 1 (ref) ··
Annual community-wide 
treatment
197 of 7446 2·6% (1·7 to 3·6) –0·3% (–4·7 to 4·2) 0·65 (0·34 to 1·24) ·· 1·20 (0·86 to 1·68) ··
Biannual community-wide 
treatment
237 of 7281 3·3% (1·8 to 4·7) –0·4% (–5·8 to 4·9) 0·80 (0·40 to 1·61) 0·41 1·01 (0·77 to 1·34) 0·43
p values correspond to the treatment group categorical variable. *Adjusted for stratification factors (subcounty, baseline cluster prevalence, and cluster size), urban or rural status and baseline cluster mean 
socioeconomic status, access to sanitation, and access to improved water. Sampling was done at randomly selected households, selecting one household member to participate at random.
Table 3: Effects of annual and biannual community-wide treatment relative to annual school-based deworming on prevalence of hookworm and Trichuris trichiura
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wide treatment group, with wide variation across the 
county (range by cluster $0·55–$1·56), and 
$0·76 per person treated per round in the biannual 
community-wide treatment group (range by cluster 
$0·49–$1·85; table 4). Within the biannual group, 
treatment round 4 (which targeted all community 
members) cost $0·68 per person treated (table 4); across 
clusters, this was a mean of $0·23 (95% CI 0·16–0·29) 
less per treatment administered than delivery alongside 
school-based deworming, which only included those 
people not treated in school. Most costs (90·5%) were 
financial (actual monies paid), and the rest were non-
financial (eg, community health volunteer opportunity 
costs). Central administration (33·6%) and drug 
administration (26·7%) were the most expensive 
activities, and personnel accounted for 67·5% of costs. 
Univariate sensitivity analysis of key selected parameters 
suggested costs were most sensitive to community 
health volunteer daily allowance. In our routine 
implementation scenario analysis, we estimated that 
community-wide treatment of the whole county 
targeting all ages would have an economic cost of $0·33 
per person treated, assuming that coverage levels 
could be maintained. This projection assumed savings 
of $0·28 per person treated per round from removing 
implementation costs that would not be incurred 
outside of the trial context and further savings of $0·07 
from economies of scale. All activities are repeated for 
each round, so a biannual strategy would be expected to 
cost approximately twice as much as an annual strategy. 
Further details of the cost results are included in the 
appendix.
During the treatment periods, trial staff were notified 
of one death attributed to malaria and one hospitalisation 
attributed to bone formation within the biannual 
treatment group as well as one hospitalisation due to 
diethylcarbamazine overdose in a community not 
included in the trial; medical review determined that 
none of these related to albendazole delivery (appendix). 
Non-serious adverse events were difficult to detect in the 
context of this trial, and none were reported.
Discussion
Community-wide treatment with albendazole significantly 
reduced the prevalence and intensity of hookworm among 
all ages compared with school-based treatment. The effect 
of community-wide treatment was similar for both annual 
and biannual treatment, and for different demographic 
and socioeconomic subgroups. Although our trial was 
short, these results are in line with the reductions 
anticipated by mathematical models developed before the 
trial,12 and highlight the potential of community-wide 
treatment targeting all ages to reduce infection prevalence 
and potentially interrupt transmission of hookworm. The 
results are also consistent with a meta-analysis that found 
that community-wide treatment was more effective than 
school-based treatment in reducing hookworm infection 
among school-aged children,6 and provide additional data 
on the effects among other age groups. An ongoing set of 
trials is investigating whether these reductions in infection 
can be translated into the interruption of transmission, 
once treatment has stopped and following a period of 
surveillance.15
Community-wide neglected tropical disease treatment 
programmes aim to achieve sustained, universal coverage. 
An acknowledged risk of universal coverage goals is that, 
without additional targeted effort, pro grammes might not 
reach the most disadvantaged groups. These groups will 
often be at increased risk of infection, which might lead to 
a rise in inequality.16 Although community health worker 
programmes have been argued to help health systems 
reach the poorest and hardest to access, remarkably few 
studies have assessed the equity of com munity health 
worker programmes adopting universal approaches, with 
nearly all those available focusing on family health, 
maternal and child health, and malaria control.17 Given 
that community-based programmes, including neglected 
tropical disease treatment, are in creasingly advocated as a 
means to ensure and monitor universal health coverage,9 
robust evidence of equity is crucial. The observation of 
high treatment coverage and equitable effects across all 
demographic and socioeconomic groups shown here is 
encouraging and suggests the use of community health 
Summary for all clusters Variation across clusters
Number of treatments 
administered*
Total cost Cost per treatment 
administered
Median number of persons 
treated (range)
Median cluster 
cost per person treated 
(range)
Annual community-wide treatment
Round 3 120 083 $101 413 $0·84 2914 (1303–6075) $0·86 (0·55–1·56)
Biannual community-wide treatment
Round 3 115 279 $100 454 $0·87 2822 (689–5892) $0·90 (0·57–2·62)
Round 4 168 130 $114 135 $0·68 4206 (1339–8410) $0·68 (0·43–1·58)
Rounds 3 and 4 283 409 $214 589 $0·76† 7246 (2121–14 302) $0·74† (0·49–1·85)
Costs presented in constant 2016 US$. *Includes only those treated by the community health volunteers and not those treated by teachers at school. †Mean cost per person 
treated per round.
Table 4: Economic cost of community-wide drug administration by trial group and round
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systems facilitated equitable delivery of the intervention. 
Future work should continue to evaluate the equity of 
neglected tropical disease treatment delivery platforms for 
access and health effects.
Several factors contributed to the high uptake of 
treatment. The intervention was delivered through a 
partnership model closely coordinated by the county 
government, but with substantial administrative and 
logistical support and training provided by trial personnel. 
This collaboration ensured a reliable distribution cascade 
for resources and drugs, while maintaining high local 
stakeholder and community ownership, and contributed 
to ongoing human resource and data capacity within the 
local health system. Community health volunteers were 
remunerated for their work, with a degree of performance-
based pay. Communication had a large role in the success 
of the programme, with community mobilisation done 
through meetings held with high-level county officers 
down to village elders and review meetings after imple-
mentation to ensure that challenges in previous rounds 
were addressed. A systematic review18 of factors that 
shape implementation of mass drug administration for 
lymphatic filariasis in sub-Saharan Africa suggested 
that programmes are particularly vulnerable to several 
elements that were carefully managed in our setting, 
including geographical demarcation of catchment areas, 
timing of drug deliveries, number of drug distributors 
and allocated households, and appropriate incentives and 
training for distributors. Therefore, caution about 
whether similar coverage can be achieved during routine 
programmatic activities is necessary.
Our high level of investment in implementation is 
reflected in the relatively high estimated economic cost of 
treating the whole community in our trial context 
($0·68 per person treated per round). Costs per person 
treated in our trial were higher still when community 
health volunteers delivered treatment immediately after 
school-based deworming, because the substantial decrease 
in the number of people targeted for treatment only led to 
a small decrease in the total cost of delivery. This finding 
calls into question the efficiency and usefulness of hybrid 
delivery platforms that maintain both school-based 
and community-based delivery of albendazole. Few high 
quality costing studies of routine delivery of neglected 
tropical disease interventions exist, and future work 
in this area is needed, but our cost estimates of soil-
transmitted helminth treatment are consistent with 
those reported by other studies.19 For example, Evidence 
Action (which supports implementation of school-based 
deworming in Kenya) reported that the total financial cost 
of the Kenya NSBDP was $0·56 per child treated in the 
2014–15 school year.20 Furthermore, our scale-up scenario 
suggests that if coverage levels can be maintained during 
routine programmatic delivery—a somewhat weighty 
assumption—the cost per person treated could be as low 
as $0·33. Further economic analyses are underway.
In 2017, the WHO expanded its strategy for control of 
soil-transmitted helminth-associated morbidity to also 
include periodic treatment of adolescent girls, women of 
reproductive age, and pregnant women and girls after 
their first trimester.2 However, the necessary operational 
guidance on how to reach these groups needs to be 
developed and provided to national programmes.21 Our 
results demonstrate that community-based treatment 
targeting all ages reached substantially more adolescent 
girls and women of reproductive age than school-based 
deworming in this setting. This suggests that community-
based treatment might provide an appropriate delivery 
mechanism as countries look to achieve long-term 
morbidity control goals in all target groups. Although 
scaling-up existing deworming programmes to target a 
broader age range increases drug and financial needs in 
the shorter term, savings in the longer term are probable 
if transmission can be interrupted and regular treatment 
is no longer required.
The observed absence of overall difference in effects 
between biannual and annual community-wide treatment 
might reflect the slow rein fection rate for hookworm.22 By 
contrast, biannual treatment might prove more effective 
against T trichiura or A lumbricoides, which are both 
characterised by reinfection rates of less than 6 months.22 
Alternatively, the absence of difference might indicate that 
the same individuals are receiving treatment in each 
round, with a core group remaining untreated, thus 
reducing any benefits provided by a second treatment 
round.23 This observation is further compounded by the 
substantially increased annual cost of delivering treatment 
using community health volunteers twice a year when 
compared with delivering treatment once a year in this 
low infection intensity setting. Longer-term follow up is 
warranted to determine whether declines in prevalence 
become more divergent with subsequent rounds of 
treatment.
Albendazole is known to have low efficacy against 
T trichiura, which might partially explain the absence of 
treatment effect seen here. Evidence highlights the 
benefit of combination therapy with albendazole plus 
ivermectin for T trichiura,24 with ivermectin now indicated 
for soil-transmitted helminths on the WHO List of 
Essential Medicines.25 The observed low prevalence and 
focal distribution of T trichiura and A lumbricoides, and 
consequent low statistical power, are also likely 
explanations for absence of differential effect by treatment 
strategy. By contrast, a non-randomised community trial 
of biannual mass treatment with albendazole done in 
Republic of Congo26 decreased the prevalence of 
A lumbricoides from 56·5% at baseline to 12·9% after 
3 years, T trichiura from 78·4% to 59·4%, and hookworm 
from 6·5% to 0%.
This trial focused exclusively on the delivery of 
treatment and did not address the adoption of sanitation 
hardware and hygiene behaviours that are important in 
reducing environmental contamination and exposure to 
soil-transmitted helminth infectious stages. Although 
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inadequate water, sanitation, and hygiene is a recognised 
risk factor for soil-transmitted helminth infection,27 there 
is less evidence of an effect of water, sanitation, and 
hygiene interventions on soil-transmitted helminth 
prevalence or intensity.28,29 This scarcity of evidence exists 
in part because these interventions are challenging to 
implement and measure at scale; they are also very costly 
relative to mass drug administration. Although access to 
sanitation was very heterogeneous across our site, the 
relative effects of the interventions were the same for 
those with access to a toilet and those without, suggesting 
that community-wide treatment was effective even in 
heavily contaminated environments.
A rational concern for programmes that rely on mass 
drug administration is the emergence of drug resistance. 
Experience of anthelmintic resistance in livestock sug-
gests that increasing the population treatment coverage 
(and hence reducing parasite refugia) might increase 
selection pressure, but the empirical evidence for this 
is mixed and we do not have conclusive evidence of 
resistance to albendazole in human soil-transmitted 
helminths, despite long-standing lymphatic filariasis pro-
grammes that provide community-wide albendazole. 
However, programmes need to routinely monitor drug 
efficacy and potential drug resistance.30
The trial had several limitations. First, due to logistical 
considerations, we were unable to do a full census before 
the start of the trial, and instead relied upon household 
lists generated in consultation with health and village 
administration, which were updated on a biannual basis. 
This reliance is reflected in the substantial increase in the 
final sampling frame, from 101 071 households at baseline 
to 147 463 at the 24-month assessment survey. However, 
no major differences occurred in household or indi-
vidual characteristics between the baseline and 24-month 
assessment surveys. However, this strategy might have 
led to us continually missing the most marginalised 
households, which might well be those at greatest 
risk of infection and the least likely to be included 
within community-wide campaigns. Second, although 
the sampling strategy used for the parasitological surveys 
was age-representative, adults, especially men, were least 
likely to consent to take part and provide a sample. Third, 
owing to implementation schedules for the national soil-
transmitted helminth and lymphatic filariasis control 
and elimination programmes, the duration since last 
treatment differed between groups; the biannual 
community-wide treatment group were treated 6 months 
later than the annual community-wide and routine 
school-based deworming groups. This difference will 
have exaggerated any differences in infection between 
annual and biannual strategies. Fourth, although 
findings from coverage surveys after treatment were 
encouraging, we found recruitment for the coverage 
survey difficult, with approximately 20% of sampled 
households unavailable during data collection. Therefore, 
included households might not be representative of the 
total population at risk, and instead might represent 
easier-to-reach households more likely to be captured 
during mass drug administration. Lastly, we relied upon 
dual Kato-Katz smears for detection of infection. Although 
this is the primary diagnostic tool recommended by 
the WHO, it is relatively insensitive especially at low 
intensities and as such we will have underestimated the 
true numbers infected.31 Newer techniques, such as 
quantitative PCR, have greater sensitivity than Kato-Katz 
(90% vs 70% sensitivity32) and are becoming increasingly 
important as infection drops to very low levels in some 
regions of the world.33 However, the lower sensitivity of 
Kato-Katz is unlikely to change the overall conclusion of 
the study, due to successful randomisation of clusters.
Since 2012, there has been remarkable scale up of 
geographically targeted school-based deworming pro-
grammes, aimed at reducing the morbidity attributable 
to soil-transmitted helminths in children. Expansion 
of treatment to all ages might support sustainable 
interruption of parasite transmission, and thus avoid the 
need for ongoing mass treatment. The results of this 
study indicate that expansion of treatment to adults 
using community health volunteers represents a fea-
sible strategy to reduce hookworm infections in the 
community. The findings also highlight the equity of the 
neglected tropical disease delivery platform, its ability to 
reach the poorest, most marginalised communities, and 
its potential to deliver other health interventions and, 
thus, contribute towards universal health-care coverage.
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